Annual report pursuant to Section 13 and 15(d)

NOTES PAYABLE (Details 1)

v3.20.4
NOTES PAYABLE (Details 1)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2019
USD ($)
Equity_Instrument
$ / shares
Dec. 31, 2018
USD ($)
Equity_Instrument
Debt Instrument [Line Items]    
Conversion Price | $ / shares $ 10.00  
Principal Outstanding $ 17,142 $ 55,172
Discount Amount 3,190 17,211
Carrying Amount $ 13,952 $ 37,961
Shares Underlying Notes | Equity_Instrument 1,444,291 6,496,892
Convertible Debentures [Member]    
Debt Instrument [Line Items]    
Principal Outstanding $ 10,200  
Discount Amount 3,185  
Carrying Amount $ 7,015  
Shares Underlying Notes | Equity_Instrument 1,080,415  
Principal Outstanding, Current $ 10,200  
Discount Amount Current 3,185  
Carrying Amount $ 7,015  
Shares Underlying Notes Current | Equity_Instrument 1,080,415  
2019 Convertible Debentures [Member]    
Debt Instrument [Line Items]    
Interest rate 10.00%  
Term of Notes 18 months  
Conversion Price | $ / shares $ 9.52  
Principal Outstanding $ 10,200  
Discount Amount 3,185  
Carrying Amount $ 7,015  
Shares Underlying Notes | Equity_Instrument [1] 1,080,415  
[1] The notes are convertible into Emmaus Life Sciences, Inc. shares.